CML is a hematologic neoplasm sustained by the constitutive activation of the BCR::ABL1 fusion kinase that can successfully be targeted with TKIs, so that most CML patients nowadays obtain durable remissions. Here, BCR is linked to hematopoietic and lymphoid system neoplasm.